Biofrontera (NASDAQ:BFRI) Upgraded to Hold at Wall Street Zen

Biofrontera (NASDAQ:BFRI) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

A number of other equities research analysts also recently commented on the company. Zacks Research downgraded Biofrontera from a “hold” rating to a “strong sell” rating in a report on Friday, July 3rd. Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Reduce”.

Biofrontera Stock Performance

Shares of BFRI stock opened at $1.09 on Friday. The company has a current ratio of 1.20, a quick ratio of 1.09 and a debt-to-equity ratio of 0.78. The stock has a 50 day simple moving average of $0.97 and a 200-day simple moving average of $0.93. The company has a market cap of $13.95 million, a price-to-earnings ratio of -1.12 and a beta of 0.81. Biofrontera has a 12-month low of $0.55 and a 12-month high of $1.21.

Biofrontera (NASDAQ:BFRI) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.29). Biofrontera had a negative net margin of 25.66% and a negative return on equity of 515.34%. The business had revenue of $10.08 million during the quarter, compared to analysts’ expectations of $10.25 million. On average, equities analysts forecast that Biofrontera will post -0.3 EPS for the current year.

Institutional Investors Weigh In On Biofrontera

An institutional investor recently raised its stake in Biofrontera stock. Geode Capital Management LLC boosted its position in Biofrontera Inc. (NASDAQ:BFRI) by 54.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the period. Geode Capital Management LLC owned about 0.56% of Biofrontera worth $37,000 as of its most recent SEC filing. 10.08% of the stock is currently owned by institutional investors and hedge funds.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.